|
2.11 Etiologie - Alimentation
|
|
|
|
|
3.1.1 Prévention - Tabac - e-cigs
|
|
|
E-cigarettes 'should be on prescription' [BBC News]
|
|
|
|
|
|
An
independent review of the latest evidence, published by PHE, suggests
at least 20,000 people a year are quitting with the help of
e-cigarettes. The report also says they are at least 95% less harmful
than smoking.
|
|
|
|
|
|
|
|
|
|
3.3 Prévention - Vaccins
|
|
|
|
3.6 Prévention - Activité physique
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
Nanopore Sequencing: The Future of NGS? [Genohub]
|
|
|
|
|
|
MinION
reads are still considerably less accurate than Illumina sequencing, so
this aspect could be improved as well. Nonetheless, this is a truly
astonishing accomplishment that indicates what the future of DNA
sequencing holds in store.
|
|
|
|
|
|
|
5. Traitements
|
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.12.10 Immunothérapies - Fusions et acquisitions
|
|
|
|
5.12.3 Immunothérapies-combinaisons
|
|
|
|
More Questions Than Answers For Bristol-Myers [Forbes]
|
|
|
|
|
|
Bristol
took the unusual step of changing one of the main goals of its study.
Clinical trials are like shooting pool: you have to call you shot before
you sink it. Bristol says it discussed the change with the Food and
Drug Administration, but did not publicly disclose it.
|
|
|
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
NICE, the NHS, and Cancer Drugs [JAMA]
|
|
|
|
|
|
The
recent increase in positive NICE recommendations for routine use likely
reflects increased willingness by the industry to offer their products
at a cost-effective price at launch to secure long-term availability in
the NHS.
|
|
|
|
|
|
|
5.5.14 ASCO (vessie)
|
|
|
|
5.5.3 ASCO (prostate)
|
|
|
|
|
|
Pfizer's Xtandi delays prostate cancer spread in early stage disease [Reuters]
|
|
|
|
|
|
The
data from a highly anticipated study released on Monday showed that it
took 36.6 months for the disease to spread to other parts of the body in
patients who received Xtandi plus androgen deprivation therapy (ADT), a
measure known as median metastasis-free survival. That compared with
14.7 months for ADT alone, a highly statistically significant difference
of nearly two years.
|
|
|
|
|
|
|
|
5.5.4 ASCO (immunothérapies)
|
|
|
|
|
|
6.6 Publications
|
|
|
Meet the New Editor-in-Chief of Cancer Research, Chi Van Dang, MD, PhD [Cancer Research Catalyst]
|
|
|
|
|
|
Cancer
science is shaped continuously by new technologies and new findings,
and as such the Convergence & Technologies section will highlight
enabling new technologies and the convergence of different disciplines
to solve key cancer research questions. Big data is now a reality in
cancer research, and the new Resource Reports section will allow for the
description of data resources that are available to cancer researchers.
|
|
|
|
|
|
|
6.8 Communication
|
|
|
Where Does the News Hype Come From? [In the Pipeline]
|
|
|
|
|
|
The
hype is coming from the press releases issued by the universities
themselves. Here’s their analysis of the problem, but before anyone
starts feeling superior to university press offices, it turns out that
the same problem exists with the PR put out by journals and publishers.
|
|
|
|
|
|